Heart failure Circulatory System
Conditions
Interventions
Exhaled breath acetone (EBA) is a biomarker of chronic heart failure (HF) diagnosis and prognosis. Levels of EBA are elevated among patients with HF, progressively increasing in correlation with worse
short or long-term devices
HT and overall mortality.
Sponsors
Universidade de São Paulo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with decompensated heart failure on inotropic support
Exclusion criteria
Exclusion criteria: Not meeting the participant inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exhaled acetone measured in breath collected in a portable non-invasive device and analyzed using spectrophotometry after reaction with salicylaldehyde at one time point | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcomes are measured using medical records during the hospitalization to 6-months follow-up: 1. Intensive care unit (ICU) admission 2. Need for devices such as an intra-aortic balloon pump, ECMO 3. Heart transplant (HT) or left ventricular assist device (LVAD) 4. Death or in-hospital HT 5. Death or HT 6. In-hospital death 7. Overall mortality | — |
Countries
Brazil
Contacts
Public ContactDaniella;Daniella Dan;Dan
;
Outcome results
None listed